Edition:
United Kingdom

MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

48.45USD
22 Jun 2018
Change (% chg)

$0.50 (+1.04%)
Prev Close
$47.95
Open
$48.10
Day's High
$49.50
Day's Low
$47.10
Volume
1,053,299
Avg. Vol
136,053
52-wk High
$62.70
52-wk Low
$12.65

Chart for

About

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializi... (more)

Overall

Beta: --
Market Cap(Mil.): $1,434.94
Shares Outstanding(Mil.): 34.96
Dividend: --
Yield (%): --

Financials

  MYOK.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -0.67 -- --
ROI: -18.14 2.00 14.38
ROE: -19.24 3.49 16.08

BRIEF-MyoKardia Announces Pricing Of Public Offering Of Common Stock

* MYOKARDIA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

23 May 2018

BRIEF-MyoKardia Says Offering 3.75 Mln Common Shares

* MYOKARDIA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

21 May 2018

BRIEF-MyoKardia Doses First Patient In Pioneer Open-Label Extension Study Of Mavacamten

* MYOKARDIA DOSES FIRST PATIENT IN PIONEER OPEN-LABEL EXTENSION STUDY OF MAVACAMTEN FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

10 May 2018

BRIEF-MyoKardia Q1 Loss Per Share $0.50

* Q1 EARNINGS PER SHARE VIEW $-0.29 -- THOMSON REUTERS I/B/E/S

08 May 2018

BRIEF-MyoKardia Begins Dosing In Phase 2 MAVERICK-HCM Clinical Trial Of Mavacamten

* HCM TRIAL ARE ANTICIPATED IN SECOND HALF OF 2019 Source text for Eikon: Further company coverage:

02 Apr 2018

BRIEF-Myokardia Files For Potential Mixed Shelf Offering

* MYOKARDIA INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2FCACNv) Further company coverage:

08 Mar 2018

BRIEF-Myokardia Reports Q4 Loss Per Share Of $0.21

* MYOKARDIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

08 Mar 2018

BRIEF-Myokardia Begins Patient Dosing In Phase 1B Clinical Study Of Myk-491

* MYOKARDIA BEGINS PATIENT DOSING IN PHASE 1B CLINICAL STUDY OF MYK-491 IN DILATED CARDIOMYOPATHY PATIENTS

14 Feb 2018

Earnings vs. Estimates